Again ... not really sure what people were expecting from the AR ? Sure there was a decrease in revenue, but 2020 FY is the revenues I would be looking hard at as it will be an indication of how the VivaGel® BV is going IMO.
I am going out on a limb here and say that I believe the ITF deal must still be rock solid or why would you put this in the AR ? If they were ready to walk IMO you wouldn't be listing it on the introductory pages / highlights ?
VivaGel® BV was licensed to ITF Pharma, Inc. for the US for milestones of up to US$101 million in addition to escalating royalties
You would also have to assume that ITF are involved in the FDA follow up processes in the USA so they must have a good idea where it is at / what is going on ? I could be wrong so don't take this as gospel
I am tipping that this will be the next licence agreement we sign IMO - again I could be wrong:
Positive independent market research was conducted in the US for SPL7013 ophthalmic drops for viral conjunctivitis and a patent was granted for the product.
SPL Price at posting:
$1.15 Sentiment: Hold Disclosure: Held
Sure there was a decrease in revenue, but 2020 FY is the revenues I would be looking hard at as it will be an indication of how the VivaGel® BV is going IMO.
